Self-Assembled Monolayers (SAMs) and gold surface modification using functionalized alkane thiols and bipodal alkane thiols based on heterobifunctional thiol alkane PEG and dithiol alkane aromatic PEG hydroxyl, carboxylate, hydrazide and biotinylated linkers/tethers for Biosensors, Nanoparticles, Imaging AFM, Microfluidics and Cryo-electron microscopy, plus cinnamaldehyde and stilbene derivative products.  


Research therapeutics for Photodynamic Therapy (laser-activated photosensitizers).  Photodynamic therapy (PDT), the treatment of disease with light and a light-activated therapeutic agent, has made strides towards a more general clinical acceptance over the past decade, but still has not reached the stage where it is recognized as a first line or primary treatment for solid subcutaneous cancerous tumors by most clinicians, including most surgeons and radiation oncologists. Until now.

the   future

In our proposed extension of the Phase II contract research, we will use Image-guided targeted one- and two-photon photodynamic therapy (TTPDT) to pursue veterinary clinical trials leading to an INDA application to FDA for treatment of small cell carcinomas in cats for whom there are no viable options.  We will also initiate animal clinical trials leading to an application for human clinical trials of our optimized therapeutic regime, developing a turn-key outpatient treatment for recurring refractory head and neck cancer that will replace current debilitating cancer treatments.

forward  thinking

Brenda D Spangler, PhD Chief Executive Officer
Charles W Spangler, PhD Chief Scientific Officer

Brenda Spangler has over 30 years experience in the field of protein chemistry and protein toxins, specializing in ligand-receptior molecular recognition - Read more in the 'About' section.

Charles Spangler has been working in the area of design and synthesis of highly conjugated organic materials for more than 30 years. His group has been involved with the design, synthesis, and characterization of new organic optical power limiting materials for eye and sensor protection, becoming one of the leaders in the design of new chromophores and dendrimers exhibiting reverse saturable absorption (RSA) and enhanced two-photon absorption (TPA) - Read more in the 'About' section.

What`s   New?

Linkers  Check out the Publications link in the About us tab for a list of publications using our linker products.  Many new and creative uses are highlighted in recent publications.

Cancer Research   SensoPath has completed a $1.5 M, 2 year NIH/National Cancer Institute SBIR contract award in collaboration with the University of Florida Dpartment of Biomedical Engineering, the College of Veterinary Medicine and the Wellman Center for Photomedicine, Massachusetts General Hospital/Harvard University for development of our Targeted Two-Photon Photodynamic Therapy therapeutic and imaging system.  

Main |  |  |  | | Contact Us